Optimi Health Ships 1,000 5mg Psilocybin Capsules to Australia for Treatment-Resistant Depression
OPTH•Optimi Health completed its third commercial export of 1,000 5mg psilocybin capsules to Australia under the Authorized Prescriber Scheme for treatment-resistant depression, reimbursed by public and private insurers. The GMP-manufactured capsules from Optimi’s Princeton facility show no serious adverse events through December 2025.
1. Third Commercial Shipment of Psilocybin Capsules
Optimi Health has exported 1,000 capsules of 5mg psilocybin to Australia, marking its third commercial shipment since launching the product in September 2025. This shipment represents recurring revenue and demonstrates growing international demand for regulated psychedelic therapies.
2. Australian Authorized Prescriber Scheme Details
Under Australia’s Authorized Prescriber Scheme, the psilocybin capsules are prescribed for treatment-resistant depression and reimbursed by public and private payers including the Department of Veterans’ Affairs and the National Disability Insurance Scheme. Over 750 clinicians have been trained to administer the therapy in expanded settings.
3. GMP Manufacturing and Safety Profile
All capsules are produced start-to-finish at Optimi’s GMP-compliant facility in Princeton, British Columbia, under Health Canada authorization. The product has recorded no serious adverse events through December 2025, reinforcing its safety profile in real-world clinical practice.
